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A previously healthy 2-year and 9-month old boy was brought to the emergency department for
a 6-day history of weakness in the legs and frequent falls, rendering him unable to walk 1 day
before admission. He did not have pain, dysphagia, bladder dysfunction, or sensory symptoms.
There was no history of trauma, but he developed diarrhea 3 days before symptom onset.
Family history was negative for consanguinity or neurologic diseases. At examination, he had
bilateral leg weakness requiring substantial aid to walk a few steps and was unable to stand up
from the floor. He had absent tendon reflexes in the lower extremities and flexor plantar
responses. Strength and reflexes in upper extremities and the rest of the examination were
normal. CSF showed a protein concentration of 125 mg/dL (NR: 15–45), with normal white
blood cell count and glucose concentration. Blood cell count and chemistry were normal, and
stool culture was negative. Nerve conduction studies (NCSs) and EMG showed decreased
amplitudes in both peroneal nerves (table e-1, links.lww.com/NXI/A131). The patient was
treated with IV immunoglobulins (IVIg) 2 g/kg administered in 3 days. During the next 2
weeks, there was mild improvement in motor strength as he was able to walk and stand up with
support (the Guillain-Barré syndrome disability scale [GBSds]1 score remained 3), and he was
discharged home. Two weeks later (4 weeks after symptom onset), he was brought back for
worsening weakness in the legs and new onset weakness in the arms. This time, the examination
revealed weakness in legs and arms, generalized areflexia, and impossibility to stand up from the
floor (GBSds 4). Repeat CSF studies showed a protein concentration of 148 mg/dL and
normal white blood cell count and glucose level. No toxic or infectious etiologies were iden-
tified, and serum was negative for ganglioside antibodies. NCSs showed prolonged distal motor
latencies, conduction slowing, and decreased amplitude of compound muscle action potentials,
along with EMG features of chronic denervation, fibrillation, and positive sharp waves (table
e-1, links.lww.com/NXI/A131). Treatment with IVIg was ineffective, but IV methylprednis-
olone (30 mg/kg/d for 5 days) resulted in substantial improvement, leaving the patient with
normal strength except for mild distal lower extremity weakness (GBSds 1).
One year later, after an episode of diarrhea, the patient developed similar clinical and electro-
physiologic abnormalities confined to the lower extremities (GBSds 3) fulfilling clinical and
electrophysiologic criteria for chronic inflammatory demyelinating polyneuropathy (CIDP). This
time, the symptom recrudescence improvedwith IVIg, and he returned to his baseline (GBSds 1).
From the Neuromuscular Unit (L.C.-G., D.N.B., C.O., J.C., A.N.), Neurology Service, Research Institute, Sant Joan de Deu Children’s Hospital, University of Barcelona; Neuromuscular
Diseases Unit (C.L., L.Q.), Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat AutónomadeBarcelona; Centro Investigación Biomédica en Red para Enfermedades
Raras (CIBERER) (C.L., J.D., L.Q., T.A.), Madrid; Neuroimmunology Program (A.S., J.D., T.A.), Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS)-Hospital Cĺınic, University of
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A recent follow-up, 5 years after symptom onset, showed that
the neurologic deficits were stable, and the patient had not had
further relapses. Current serum studies for antibodies against
components of the nodal and paranodal regions of peripheral
nerves were negative, but analysis of archived serum and CSF
samples obtained at disease onset (5 years earlier) showed
intense reactivity with teased nerve fibers from pig and human
embrionic kidney (HEK) 293 cells expressing contactin-1
demonstrating the presence of these antibodies in both assays
(figure).
Discussion
CIDP is a rare, disabling and treatable disease in children.
Antibodies against proteins of the paranode and node of
Ranvier (contactin-1, contactin-associated protein 1, and
neurofascin 155 and 186) have been recently described in
several subsets of patients with CIDP.2 In particular, CIDP
associated with antibodies against the 155 isoform of neuro-
fascin develop at younger ages, including pediatric patients.2,3
However, antibodies against contactin-1 have never been
reported in children. These antibodies are predominantly
IgG4 subclass and associate with a form of CIDP that mani-
fests with an aggressive symptom onset, resembling Guillain-
Barré syndrome, with predominant motor weakness, ataxia,
and absent or limited response to IVIg or steroids but an
excellent response to rituximab.4,5 This disorder represents
approximately 2%–4% of all patients with CIDP. Clinical
improvement is usually accompanied by a decrease of
contactin-1 antibody titers.6,7 Our patient had a similar pre-
sentation with predominant motor involvement and NCSs
and EMG suggesting demyelinating features accompanied by
early axonal damage. However, he had a less aggressive course
compared with that described in adults. Because at the last
follow-up, 5 years after disease onset, the patient’s deficits had
remained stable for 4 years, treatment with rituximab was not
considered. It is likely that an earlier recognition of the dis-
order, by examining contactin-1 antibodies at disease onset,
would have prompted treatment with rituximab and perhaps
prevented some of his deficits.
Experience with this patient indicates that contactin-1
antibody-associated CIDP can occur in children. Testing for
antibodies against nodo-paranodal proteins is important in
pediatric patients with CIDP refractory to conventional ther-
apies because antibody findings can help optimizing their care.
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Disclosure
J. Dalmau receives royalties from Athena Diagnostics for the use
of Ma-2 as an autoantibody test and from Euroimmun AG for
the use of NMDA, GABAB receptor, GABAA receptor, DPPX,
and IgLON5 as autoantibody tests and is Editor of Neurology:
Neuroimmunology & Neuroinflammation. The other authors re-
port no relevant disclosures. Go to Neurology.org/NN for full
disclosures.
Figure Demonstration of anti–contactin-1 antibodies in a serum of a child with CIDP
The presence of anti–contactin-1 antibodies was confirmed with contactin-1–transfected human embrionic kidney (HEK) 293 cells. Patient serum (B) showed
strong reactivity against contactin-1 and colocalized with the reactivity of a commercial antibody (A) in merged images (C). Patient serum showed strong
reactivity against the paranode on pig teased nerve fibers (E) and colocalized with the reactivity of a commercial antibody (D) in merged images (F).
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